On Feb. 22, 2021, Amyris announced highly promising preliminary data in a pre-clinical study of its ribonucleic acid (RNA) COVID-19 vaccine platform as well as the potential to address current manufacturing, supply scale-up and refrigerated storage and distribution challenges.

In October 2020, Amyris announced a collaboration agreement and exclusive license with the Infectious Disease Research Institute (IDRI) to advance a novel RNA vaccine platform, including the development of a COVID-19 vaccine. Preliminary data from a pre-clinical study of IDRI’s Nanostructured Lipid Carrier vaccine platform demonstrated a significant level of antibody production against the COVID-19 spike protein using a self-adjuvanting RNA vaccine.